Healthcare shares are flat in pre-market trade.
ISIS Pharmaceuticals (
) said Monday that it has earned a $2 million milestone payment
from GlaxoSmithKline (
) related to the advancement of the ongoing Phase 2/3 study of
ISIS-TTR Rx in patients with familial amyloid polyneuropathy
ISIS-TTR Rx is an antisense drug which ISIS is developing with
GSK for the treatment of transthyretin amyloidosis, a severe and
rare genetic disease characterized by progressive dysfunction of
peripheral nerve and/or heart tissues.
And, UnitedHealth Group (
) affirmed its previous outlook for 2013 net earnings of $5.40 to
$5.50 per share. The Street view is for $5.49 per share, according
to Capital IQ.
UNH management says it will discuss the company's 2014 financial
outlook, which includes revenues of $128 billion to $129 billion
and net earnings of $5.40 to $5.60 per share, tomorrow. The Street
is at $132 billion in revenue and earnings of $5.68 per share.
Finally, Orexigen Therapeutics (
), a biopharmaceutical company focused on the treatment of obesity,
is down 5% in pre-market after it says it has begun a $100 million
private offering of aggregate principal amount of convertible
senior notes due 2020. The company expects to grant the initial
purchasers a 13-day option to purchase up to an additional $15
million aggregate principal amount of such notes.
OREX intends to use the net proceeds from the offering for
working capital and other general corporate purposes.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.